This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marty, F. M.
Right arrow Articles by Pillai, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marty, F. M.
Right arrow Articles by Pillai, S. K.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 2006, p. 595-597, Vol. 44, No. 2
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.2.595-597.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis

Francisco M. Marty,1,4,5* Wendy W. Yeh,1,5 Christine B. Wennersten,3 Lata Venkataraman,3 Esperanza Albano,1 Edwin P. Alyea,2,4,5 Howard S. Gold,3,5 Lindsey R. Baden,1,4,5 and Satish K. Pillai3,5

Division of Infectious Diseases,1 Division of Medical Oncology, Brigham & Women's Hospital,2 Division of Infectious Diseases, Beth Israel Deaconess Medical Center,3 Dana-Farber Cancer Institute,4 Harvard Medical School, Boston, Massachusetts5

Received 15 September 2005/ Accepted 2 November 2005

The emergence of a clinically daptomycin-resistant Staphylococcus aureus isolate occurred during treatment of methicillin-resistant S. aureus bacteremia and probable vertebral osteomyelitis. The breakthrough isolate was indistinguishable from pretreatment daptomycin-susceptible isolates by pulsed-field gel electrophoresis. Daptomycin nonsusceptibility was confirmed by MIC and time-kill curve analyses.

* Corresponding author. Mailing address: Division of Infectious Diseases, Brigham & Women's Hospital, 75 Francis Street, PBB-A4, Boston, MA 02115. Phone: (617) 732-8881. Fax: (617) 732-6829. E-mail: fmarty{at}partners.org.

Journal of Clinical Microbiology, February 2006, p. 595-597, Vol. 44, No. 2
0095-1137/06/$08.00+0     doi:10.1128/JCM.44.2.595-597.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pantosti, A., Venditti, M. (2009). What is MRSA?. Eur Respir J 34: 1190-1196 [Abstract] [Full Text]  
  • Miro, J. M., Garcia-de-la-Maria, C., Armero, Y., Soy, D., Moreno, A., del Rio, A., Almela, M., Sarasa, M., Mestres, C. A., Gatell, J. M., Jimenez de Anta, M. T., Marco, F., and the Hospital Clinic Experimental Endocarditis, (2009). Addition of Gentamicin or Rifampin Does Not Enhance the Effectiveness of Daptomycin in Treatment of Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 4172-4177 [Abstract] [Full Text]  
  • Moise, P. A, Hershberger, E., Amodio-Groton, M. I, Lamp, K. C (2009). Safety and Clinical Outcomes when Utilizing High-Dose (>=8 mg/kg) Daptomycin Therapy. The Annals of Pharmacotherapy 43: 1211-1219 [Abstract] [Full Text]  
  • Camargo, I. L. B. d. C., Neoh, H.-M., Cui, L., Hiramatsu, K. (2008). Serial Daptomycin Selection Generates Daptomycin-Nonsusceptible Staphylococcus aureus Strains with a Heterogeneous Vancomycin-Intermediate Phenotype. Antimicrob. Agents Chemother. 52: 4289-4299 [Abstract] [Full Text]  
  • Warren, R. E. (2008). Daptomycin in endocarditis and bacteraemia: a British perspective. J Antimicrob Chemother 62: iii25-iii33 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Rybak, M. J. (2008). Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 3061-3067 [Abstract] [Full Text]  
  • Murthy, M. H., Olson, M. E., Wickert, R. W., Fey, P. D., Jalali, Z. (2008). Daptomycin non-susceptible meticillin-resistant Staphylococcus aureus USA 300 isolate. J Med Microbiol 57: 1036-1038 [Abstract] [Full Text]  
  • Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., Rybak, M. J. (2008). Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations. Antimicrob. Agents Chemother. 52: 831-836 [Abstract] [Full Text]  
  • Huang, Y.-T., Hsiao, C.-H., Liao, C.-H., Lee, C.-W., Hsueh, P.-R. (2008). Bacteremia and Infective Endocarditis Caused by a Non-Daptomycin-Susceptible, Vancomycin-Intermediate, and Methicillin-Resistant Staphylococcus aureus Strain in Taiwan. J. Clin. Microbiol. 46: 1132-1136 [Abstract] [Full Text]  
  • Jones, T., Yeaman, M. R., Sakoulas, G., Yang, S.-J., Proctor, R. A., Sahl, H.-G., Schrenzel, J., Xiong, Y. Q., Bayer, A. S. (2008). Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding. Antimicrob. Agents Chemother. 52: 269-278 [Abstract] [Full Text]  
  • Sakoulas, G., Rose, W., Rybak, M. J., Pillai, S., Alder, J., Moellering, R. C. Jr., Eliopoulos, G. M. (2008). Evaluation of Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus Developing Nonsusceptibility to Daptomycin. J. Clin. Microbiol. 46: 220-224 [Abstract] [Full Text]  
  • Rose, W. E., Rybak, M. J., Kaatz, G. W. (2007). Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 60: 334-340 [Abstract] [Full Text]  
  • Falagas, M. E., Giannopoulou, K. P., Ntziora, F., Vardakas, K. Z. (2007). Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother 60: 7-19 [Abstract] [Full Text]  
  • Pillai, S. K., Gold, H. S., Sakoulas, G., Wennersten, C., Moellering, R. C. Jr., Eliopoulos, G. M. (2007). Daptomycin Nonsusceptibility in Staphylococcus aureus with Reduced Vancomycin Susceptibility Is Independent of Alterations in MprF. Antimicrob. Agents Chemother. 51: 2223-2225 [Abstract] [Full Text]  
  • French, G. L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. J Antimicrob Chemother 58: 1107-1117 [Abstract] [Full Text]  
  • Tyrrell, K. L., Citron, D. M., Warren, Y. A., Fernandez, H. T., Merriam, C. V., Goldstein, E. J. C. (2006). In Vitro Activities of Daptomycin, Vancomycin, and Penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes.. Antimicrob. Agents Chemother. 50: 2728-2731 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»